Successful thrombolytic treatment of neonatal arterial thromboses

Summary

Compared to children of other age groups neonates show an increased thrombotic risk. The acute therapy depends on thrombus age, the localisation of vascular occlusion and the severity of the underlying disease. The treatment of choice is represented by the administration of unfractionated (UFH) or low molecular weight heparin (LMWH). If loss of limbs or organs is imminent, the application of thrombolytic treatment with recombinant tissue-type plasminogen activator (rt-PA) should be considered whilst taking into account the associated bleeding risk. We report on two patients in which thrombolytic therapy has been conducted successfully.

Zusammenfassung

Neugeborene weisen im Vergleich zu Kindern anderer Altersgruppen ein erhöhtes Thromboserisiko auf. Die Akuttherapie orientiert sich am Alter der Thrombose, der Lokalisation des Gefäßverschlusses sowie der Schwere der Grunderkrankung. Die Behandlung der Wahl stellt die Gabe von unfraktioniertem (UFH) oder niedermolekularem Heparin (LMWH) dar. Bei drohendem Verlust von Extremitäten oder Organen sollte eine thrombolytische Therapie mit rekombinantem Gewebsplasminogenaktivator (rt-PA) unter Berücksichtigung des Blutungsrisikos erwogen werden. Wir berichten von zwei Patienten, bei denen eine thrombolytische Therapie erfolgreich durchgeführt werden konnte.

Keywords

Neonates - thrombosis - thrombolytic therapy

Schlüsselwörter

Neugeborene - Thrombose - thrombolytische Therapie

• References

• 1 Albisetti M. Thrombolytic therapy in children. Thromb Res 2006; 118: 95-105.
• 2 Andrew M, Brooker L, Leaker M. et al. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration. Thromb Haemost 1992; 68: 325-330.
• 3 Andrew M, David M, Adams M. et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994; 83: 1251-1257.
• 4 Gupta AA, Leaker M, Andrew M. et al. Safety and outcomes of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children. J Pediatr 2001; 139 (05) 682-8.
• 5 Hartmann J, Hussein A, Trowitzsch E. et al. Treatment of neonatal thrombus formation with recombinant tissue plasminogen activator: six years experience and review of the literature. Arch Dis Child Fetal Neonatal Ed 2001; 85: F18-F22.
• 6 Knöfler R, Dinger J, Kabus M. et al. Thrombolytic therapy in children - Clinical experiences with recombinant tissue-plasminogen activator. Semin Thromb Hemost 2001; 27: 169-174.
• 7 Leaker M, Massicotte MP, Brooker LA, Andrew M. Thrombolytic therapy in pediatric patients: a comprehensive review of the literature. Thromb Haemost 1996; 76: 132-134.
• 8 Long E, Pitfield AF, Kissoon N. Anticoagulation therapy: indications, monitoring, and complications. Pediatr Emerg Care 2011; 27: 55-61.
• 9 Manco-Johnson MJ, Nuss R, Hays T. et al. Combined thrombolytic and anticoagulant therapy for venous thrombosis in children. J Pediatr 2000; 136: 446-453.
• 10 Manco-Johnson MJ, Grabowski EF, Hellgreen M. et al. Recommendations for tPA thrombolysis in children. On behalf of the Scientific Subcommittee on Perinatal and Pediatric Thrombosis of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost 2002; 88: 157-158.
• 11 Monagle P, Chan AK, Goldenberg NA. et al. American College of Chest Physicians. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis. Chest 2012; 141 (2 Suppl): 737-801.
• 12 Newall F, Browne M, Savoia H. et al. Assessing the outcome of systemic tissue plasminogen activator for the management of venous and arterial thrombosis in pediatrics. J Pediatr Hematol Oncol 2007; 29: 269-273.
• 13 Nowak-Göttl U, von Kries R, Göbel U. Neonatal symptomatic thromboembolism in Germany: two year survey. Arch Dis Child Fetal Neonatal Ed 1997; 76: F163-F167.
• 14 Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry. Pediatrics 1995; 96: 939-943.
• 15 Wang M, Hays T, Balasa V. et al. Pediatric Coagulation Consortium. Low-dose tissue plasminogen activator thrombolysis in children. J Pediatr Hematol Oncol 2003; 25: 379-386.
• 16 Williams MD. Thrombolysis in children. Br J Haematol 2010; 148: 26-36.
• 17 Yurka HG, Wissler RN, Zanghi CN. et al. Congenital Heart Surgery Research Interest Group. The effective concentration of epsilon-aminocaproic Acid for inhibition of fibrinolysis in neonatal plasma in vitro. Anesth Analg 2010; 111: 180-184.
• 18 Zenz W, Arlt F, Sodia S, Berghold A. Intracerebral hemorrhage during fibrinolytic therapy in children: a review of the literature of the last thirty years. Semin Thromb Hemost 1997; 23: 321-332.